News | Stents Drug Eluting | January 02, 2023

FDA Approves BioFreedom Drug Coated Coronary Stent (DCS) System – P190020

The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DCS) System – P190020 from Biosensors International. 

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DCS) System – P190020 from Biosensors International. The BioFreedom Drug Coated Coronary Stent System is intended to treat a narrowed blood vessel (coronary artery) caused by coronary artery disease. The system consists of a catheter delivery system and a 316L stainless steel metal stent. The stent is coated with the drug Biolimus A9. This stent does not contain any additional elements called polymers or carriers to control the release of the drug.

A doctor inserts the BioFreedom Drug Coated Coronary Stent System’s delivery balloon catheter into a blood vessel in a patient’s arm or groin. The stent is then positioned at the site of the coronary artery and the balloon is inflated. The stent expands and is pressed against the coronary artery wall. The stent remains permanently implanted within the coronary artery to help keep it open and improve the supply of blood and oxygen to the heart. The drug (Biolimus A9) is released over time from the BioFreedom stent surface into the coronary artery wall to help prevent re-narrowing, which sometimes occurs after the stent is implanted.

The BioFreedom Drug Coated Coronary Stent System is used in people who have narrowed coronary arteries and are at high risk for bleeding due to previous conditions including:

  • Advanced age
  • The need for chronic or lifelong anticoagulants (blood thinning medicines such as heparin and others that slow down the process of making blood clots) 
  • History of major bleeding, stroke, or kidney (renal) insufficiency.

In the primary clinical study, 1,203 patients at high risk for bleeding were treated using the BioFreedom stent and were able to stop taking one of their two antiplatelet therapy medicines (blood thinning medicines such as aspirin and others that prevent blood cells called platelets from clumping together to make a clot) after one month. The results showed that people with the stent who stopped taking one blood thinner one month after stent implant, but kept taking aspirin, were not at increased risk of death or heart attack (myocardial infarction) in the first year, compared to people treated with a non-drug coated stent in an earlier study.

The BioFreedom DCS System should not be used:

  • If the patient cannot take blood-thinning medications (also called antiplatelet or anticoagulant therapy)
  • If a doctor decides that the coronary artery blockage will not allow complete inflation of the angioplasty balloon.
  • If there is a known hypersensitivity (allergy) or other reason not to use Biolimus A9 or the structurally related compounds such as stainless steel, nickel or other metal ions found in 316L.
  • If there is a known hypersensitivity (allergy) or other reason not to use contrast agents that will be used for the implantation of the stent.

For more information: www.fda.gov

Related Coronary Stent Content:

The Next Step in Bioresorbable Stent Technologies

VIDEO: The Current State of Bioresorbable Stents in 2018 — Interview with Patrick Serruys, M.D.

VIDEO: Use of the Tryton Dedicated Bifurcation Stent — Interview with Philippe Genereux, M.D.

VIDEO: What Went Wrong With the Absorb Stent? — Interview with Ajay Kirtane, M.D.


Related Content

News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Stents Drug Eluting

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...

Home October 11, 2019
Home
News | Stents Drug Eluting

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target ...

Home September 05, 2019
Home
Subscribe Now